In the main frame of the above research topic, 16 contributions have been published including but not limited to the comparative pharmacokinetics between normal and disease status, the changes in the expression and function of drug-metabolizing enzymes and drug transporters in disease status and their related regulatory mechanisms, ADME/toxicity of drugs as well as their regulation, drug-drug interactions mediated by nuclear receptors, transporters and metabolic enzymes based on the methods and techniques of pharmacokinetics, transcriptomics, and metabolomics. However , the pharmacokinetic study is not only crucial in the development of new drugs, but also the study of pharmacokinetic-pharmacokinetic(PK-PD) model plays an important role in the process of new drug development. PK-PD model can reveal the internal relationship between drug concentration and effect, help to understand the dynamic characteristics of the drug action site in vivo and deduce the action site producing effect and drug concentration at the action site, which enables researchers to recognize the comprehensive characteristics of drug PK and PD processes in vivo. However, preclinical pharmacokinetic data are mainly derived from healthy animals, which is unreasonable. On the one hand, patients are the final consumers of drugs because drugs are mainly used to treat patients with diseases. On the other hand, whether the body is in a pathological state and the severity of the disease have different effects on the ADMEof drugs, which is closely related to whether the clinical drug is safe and effective. Therefore, studying the pharmacokinetics and PK-PD model in disease states is more meaningful and clinically relevant.